UnknownNot Applicable

The Effect of Solifenacin Used for Lower Urinary Tract Symptoms on Sexual Function

Turkey (Türkiye)150 participantsStarted 2021-06-03

Plain-language summary

This study aims to determine whether Solifenacine used for lower urinary tract symptoms improves sexual function and if so does this improvement differs between premenopausal and postmenopausal women.

Who can participate

Age range18 Years – 90 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that are planned to start treatment with Solifenacin 5 mg (Vesicare 5mg). * Patients agreed to involve in the study, having discussed other treatment options and possible side effects of the medication. * Informed consent obtained Exclusion Criteria: * urinary tract infection * stress urinary incontinence * urinary retention * grade 2 or above pelvic organ prolapse according to POP-Q scale * Solifenacin contraindications such as narrow angle glaucoma, allergy of Solifenacin or other components of the drug.

What they're measuring

the effect of solifenasin used for lower urinary tract symptoms on sexual function

Timeframe: 6 months

the effect of solifenasin used for lower urinary tract symptoms on sexual function in premenapausal vs postmenapausal women

Timeframe: 6 months

Trial details

NCT IDNCT05391425

SponsorIstanbul University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06-03

Contact for this trial

Inci Sema Tas, MD

00905359509232 incisematas@gmail.com

View on ClinicalTrials.gov More Urge Incontinence trials